JP2011515495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515495A5 JP2011515495A5 JP2011502067A JP2011502067A JP2011515495A5 JP 2011515495 A5 JP2011515495 A5 JP 2011515495A5 JP 2011502067 A JP2011502067 A JP 2011502067A JP 2011502067 A JP2011502067 A JP 2011502067A JP 2011515495 A5 JP2011515495 A5 JP 2011515495A5
- Authority
- JP
- Japan
- Prior art keywords
- opioid
- prodrug
- antagonist
- abuse
- opioid agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000651 prodrug Substances 0.000 claims 43
- 229940002612 prodrug Drugs 0.000 claims 43
- 239000003402 opiate agonist Substances 0.000 claims 25
- 239000003401 opiate antagonist Substances 0.000 claims 21
- 239000005557 antagonist Substances 0.000 claims 20
- -1 desomorphin Chemical compound 0.000 claims 16
- 239000011248 coating agent Substances 0.000 claims 12
- 238000000576 coating method Methods 0.000 claims 12
- 239000011159 matrix material Substances 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000000853 adhesive Substances 0.000 claims 8
- 230000001070 adhesive effect Effects 0.000 claims 8
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 6
- 229960001736 buprenorphine Drugs 0.000 claims 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 229960003461 dezocine Drugs 0.000 claims 6
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 6
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 6
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 6
- 229960000805 nalbuphine Drugs 0.000 claims 6
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 6
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 6
- 229960003086 naltrexone Drugs 0.000 claims 6
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 claims 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims 4
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 claims 3
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 claims 3
- LGFMXOTUSSVQJV-NEYUFSEYSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;1-[(3,4-dimethoxyphenyl)methyl]-6 Chemical compound Cl.Cl.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 LGFMXOTUSSVQJV-NEYUFSEYSA-N 0.000 claims 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 3
- IYNWSQDZXMGGGI-NUEKZKHPSA-N 3-hydroxymorphinan Chemical compound C1CCC[C@H]2[C@H]3CC4=CC=C(O)C=C4[C@]21CCN3 IYNWSQDZXMGGGI-NUEKZKHPSA-N 0.000 claims 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 3
- JLVNEHKORQFVQJ-PYIJOLGTSA-N 6alpha-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 3
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 3
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 3
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 3
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims 3
- 239000008896 Opium Substances 0.000 claims 3
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 3
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 3
- 229960001391 alfentanil Drugs 0.000 claims 3
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 3
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 3
- 229960001113 butorphanol Drugs 0.000 claims 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 3
- 229960004126 codeine Drugs 0.000 claims 3
- 229950002213 cyclazocine Drugs 0.000 claims 3
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims 3
- 229960003701 dextromoramide Drugs 0.000 claims 3
- 229960004193 dextropropoxyphene Drugs 0.000 claims 3
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 3
- 229960000920 dihydrocodeine Drugs 0.000 claims 3
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 3
- RHUWRJWFHUKVED-UHFFFAOYSA-N dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 claims 3
- 229950011187 dimenoxadol Drugs 0.000 claims 3
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims 3
- CANBGVXYBPOLRR-UHFFFAOYSA-N dimethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)C)C1=CC=CS1 CANBGVXYBPOLRR-UHFFFAOYSA-N 0.000 claims 3
- 229950005563 dimethylthiambutene Drugs 0.000 claims 3
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims 3
- 229960002500 dipipanone Drugs 0.000 claims 3
- 229960002428 fentanyl Drugs 0.000 claims 3
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 3
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 3
- 229960000240 hydrocodone Drugs 0.000 claims 3
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 3
- 229960001410 hydromorphone Drugs 0.000 claims 3
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 claims 3
- 229950009272 isomethadone Drugs 0.000 claims 3
- IMYHGORQCPYVBZ-UHFFFAOYSA-N lofentanyl Chemical group C1CN(CCC=2C=CC=CC=2)CC(C)C1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 IMYHGORQCPYVBZ-UHFFFAOYSA-N 0.000 claims 3
- 229960000365 meptazinol Drugs 0.000 claims 3
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims 3
- YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 claims 3
- 229950009131 metazocine Drugs 0.000 claims 3
- 229960001797 methadone Drugs 0.000 claims 3
- 229960005181 morphine Drugs 0.000 claims 3
- 229950007471 myrophine Drugs 0.000 claims 3
- GODGZZGKTZQSAL-VXFFQEMOSA-N myrophine Chemical compound C([C@@H]1[C@@H]2C=C[C@@H]([C@@H]3OC4=C5[C@]23CCN1C)OC(=O)CCCCCCCCCCCCC)C5=CC=C4OCC1=CC=CC=C1 GODGZZGKTZQSAL-VXFFQEMOSA-N 0.000 claims 3
- 229960005297 nalmefene Drugs 0.000 claims 3
- 229960004127 naloxone Drugs 0.000 claims 3
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 3
- 229950011519 norlevorphanol Drugs 0.000 claims 3
- 229960004013 normethadone Drugs 0.000 claims 3
- WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 claims 3
- 229950007418 norpipanone Drugs 0.000 claims 3
- WCDSHELZWCOTMI-UHFFFAOYSA-N norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 claims 3
- 229960001027 opium Drugs 0.000 claims 3
- 229960002085 oxycodone Drugs 0.000 claims 3
- 229960005118 oxymorphone Drugs 0.000 claims 3
- 229960003294 papaveretum Drugs 0.000 claims 3
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 3
- 229960005301 pentazocine Drugs 0.000 claims 3
- 229960000482 pethidine Drugs 0.000 claims 3
- LOXCOAXRHYDLOW-UHFFFAOYSA-N phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 claims 3
- 229950004540 phenadoxone Drugs 0.000 claims 3
- CFBQYWXPZVQQTN-QPTUXGOLSA-N phenomorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CCC1=CC=CC=C1 CFBQYWXPZVQQTN-QPTUXGOLSA-N 0.000 claims 3
- 229950011496 phenomorphan Drugs 0.000 claims 3
- 229960004315 phenoperidine Drugs 0.000 claims 3
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims 3
- XJKQCILVUHXVIQ-UHFFFAOYSA-N properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 claims 3
- 229950004345 properidine Drugs 0.000 claims 3
- 229960004739 sufentanil Drugs 0.000 claims 3
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 3
- 229960004380 tramadol Drugs 0.000 claims 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 3
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 claims 2
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 claims 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 2
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims 2
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims 2
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 239000005642 Oleic acid Substances 0.000 claims 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims 2
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 claims 2
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims 2
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 2
- 229940031578 diisopropyl adipate Drugs 0.000 claims 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 claims 2
- 229950010920 eptazocine Drugs 0.000 claims 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims 2
- 229940093471 ethyl oleate Drugs 0.000 claims 2
- 229960004578 ethylmorphine Drugs 0.000 claims 2
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 claims 2
- 229950004155 etorphine Drugs 0.000 claims 2
- 229940068939 glyceryl monolaurate Drugs 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960000938 nalorphine Drugs 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 229940055577 oleyl alcohol Drugs 0.000 claims 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 2
- 150000003505 terpenes Chemical class 0.000 claims 2
- 235000007586 terpenes Nutrition 0.000 claims 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 claims 2
- 229940100640 transdermal system Drugs 0.000 claims 2
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 claims 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 1
- 229940127450 Opioid Agonists Drugs 0.000 claims 1
- 229960003029 ketobemidone Drugs 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- PXXKIYPSXYFATG-UHFFFAOYSA-N piminodine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCCNC1=CC=CC=C1 PXXKIYPSXYFATG-UHFFFAOYSA-N 0.000 claims 1
- 229950006445 piminodine Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3976308P | 2008-03-26 | 2008-03-26 | |
| US61/039,763 | 2008-03-26 | ||
| PCT/US2009/038439 WO2009120889A2 (en) | 2008-03-26 | 2009-03-26 | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011515495A JP2011515495A (ja) | 2011-05-19 |
| JP2011515495A5 true JP2011515495A5 (enExample) | 2012-05-24 |
Family
ID=40809924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502067A Pending JP2011515495A (ja) | 2008-03-26 | 2009-03-26 | オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090246265A1 (enExample) |
| EP (1) | EP2254561A2 (enExample) |
| JP (1) | JP2011515495A (enExample) |
| CA (1) | CA2718943A1 (enExample) |
| MX (1) | MX2010010512A (enExample) |
| WO (1) | WO2009120889A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| CA2687979C (en) | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of risperidone compounds |
| KR101660996B1 (ko) * | 2008-09-16 | 2016-09-28 | 넥타르 테라퓨틱스 | 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드 |
| US8386274B1 (en) | 2008-09-17 | 2013-02-26 | Mckesson Financial Holdings Limited | Systems and methods for a prescription safety network utilizing eligibility verification transactions |
| ES2592277T3 (es) * | 2010-04-02 | 2016-11-29 | Buzzz Pharmaceuticals Limited | Formulaciones transdérmicas disuasorias del abuso de agonistas y agonistas-antagonistas opiáceos |
| US8392219B1 (en) | 2010-05-10 | 2013-03-05 | Mckesson Financial Holdings Limited | Systems and methods for streamlined patient enrollment for one or more healthcare programs |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| GB2481619B (en) * | 2010-06-30 | 2012-06-20 | Londonpharma Ltd | Formulations and delivery devices for the sublingual administration of opioids |
| US20120225112A1 (en) * | 2011-03-03 | 2012-09-06 | Mark Stephen Saia | Method and Apparatus for Alcohol Administration |
| US9566341B1 (en) | 2011-04-27 | 2017-02-14 | University Of Kentucky Research Foundation | Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same |
| US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| US9283175B2 (en) | 2011-07-28 | 2016-03-15 | Ian S. Zagon | Methods and compositions for treatment of epithelial wounds |
| HK1206978A1 (en) | 2012-04-17 | 2016-01-22 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| US20140170593A1 (en) * | 2012-12-18 | 2014-06-19 | Oltuse, Llc | Patch for non-invasive pain relief |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| JP2016529328A (ja) | 2013-09-10 | 2016-09-23 | インシス・ファーマ・インコーポレーテッド | 舌下ブプレノルフィンスプレー |
| US9839611B2 (en) | 2013-09-10 | 2017-12-12 | Insys Development Company, Inc. | Sublingual buprenorphine spray |
| US9867818B2 (en) | 2013-09-10 | 2018-01-16 | Insys Development Company, Inc. | Sublingual buprenorphine spray |
| US9918981B2 (en) | 2013-09-10 | 2018-03-20 | Insys Development Company, Inc. | Liquid buprenorphine formulations |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| CA2954370A1 (en) | 2014-07-08 | 2016-01-14 | Insys Pharma, Inc. | Sublingual naloxone spray |
| US10722510B2 (en) | 2014-07-08 | 2020-07-28 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US10617686B2 (en) | 2014-07-08 | 2020-04-14 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| TW201613590A (en) * | 2014-09-12 | 2016-04-16 | Purdue Pharma Lp | Systems and methods for attenuating opioid-induced euphoria |
| KR102102513B1 (ko) * | 2014-10-14 | 2020-04-20 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US10496793B1 (en) | 2014-12-15 | 2019-12-03 | Mckesson Corporation | Systems and methods for determining eligibility in a prescription safety network program |
| US10010543B1 (en) | 2014-12-23 | 2018-07-03 | Barr Laboratories, Inc. | Transdermal dosage form |
| CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
| WO2016145373A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
| WO2017040607A1 (en) * | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
| GB201520390D0 (en) * | 2015-11-19 | 2016-01-06 | Euro Celtique Sa | Composition |
| US20170273974A1 (en) * | 2016-03-24 | 2017-09-28 | Medrx Co., Ltd | Patch preparations with misuse prevention features |
| WO2018075665A1 (en) * | 2016-10-20 | 2018-04-26 | Axim Biotechnologies, Inc. | Chewing gum composition comprising cannabinoids and opioid agonists and/or antagonists |
| CN110121344A (zh) * | 2016-12-28 | 2019-08-13 | 久光制药株式会社 | 含布托啡诺的贴附剂 |
| EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| JP6773897B2 (ja) | 2017-04-25 | 2020-10-21 | 久光製薬株式会社 | 貼付剤 |
| CN110545816B (zh) | 2017-04-25 | 2023-04-11 | 久光制药株式会社 | 贴附剂 |
| CA3068036A1 (en) | 2017-06-30 | 2019-01-03 | Purdue Pharma L.P. | Use to buprenorphine in combination with an opioid to treat pain |
| AU2018359336B2 (en) | 2017-11-03 | 2024-06-20 | Nirsum Laboratories, Inc. | Opioid receptor antagonist prodrugs |
| JP2021506790A (ja) * | 2017-12-14 | 2021-02-22 | エルテーエス ローマン テラピー−ジステーメ アーゲー | 塩形態の有効成分を含むマイクロニードルアレイ |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| WO2020012248A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Novel naphthylenyl compounds for long-acting injectable compositions and related methods |
| US10807995B2 (en) | 2018-07-13 | 2020-10-20 | Alkermes Pharma Ireland Limited | Thienothiophene compounds for long-acting injectable compositions and related methods |
| US10975099B2 (en) | 2018-11-05 | 2021-04-13 | Alkermes Pharma Ireland Limited | Thiophene compounds for long-acting injectable compositions and related methods |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| CN113226288B (zh) * | 2018-12-27 | 2023-04-28 | 昱展新药生技股份有限公司 | 纳曲酮注射型缓释制剂 |
| JP7397095B2 (ja) | 2019-05-07 | 2023-12-12 | ニーサム・ラボラトリーズ・インコーポレイテッド | オピオイド受容体アンタゴニストプロドラッグ |
| WO2023022050A1 (ja) * | 2021-08-17 | 2023-02-23 | 株式会社カネカ | アミノアルキルテトラヒドロピラン誘導体 |
| CN114949220B (zh) * | 2022-01-30 | 2023-09-22 | 浙江大学 | 一种靶向损伤节段背根神经节的pH响应镇痛药及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
| US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
| FR2519985A1 (fr) * | 1982-01-15 | 1983-07-22 | Ugine Kuhlmann | Procede perfectionne de fabrication de l'e-caprolactone |
| US4780320A (en) * | 1986-04-29 | 1988-10-25 | Pharmetrix Corp. | Controlled release drug delivery system for the periodontal pocket |
| US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
| US5006342A (en) * | 1986-12-22 | 1991-04-09 | Cygnus Corporation | Resilient transdermal drug delivery device |
| US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
| US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
| US5288502A (en) * | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
| US5919473A (en) * | 1997-05-12 | 1999-07-06 | Elkhoury; George F. | Methods and devices for delivering opioid analgesics to wounds via a subdermal implant |
| US7011843B2 (en) * | 1997-10-01 | 2006-03-14 | Lts Lohmann-Therapie Systeme Ag | Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system |
| US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| PT2062573E (pt) * | 2001-05-01 | 2012-01-11 | Euro Celtique Sa | Sistemas transdérmicos que contêm opióides que resistem a violação |
| US6913760B2 (en) * | 2001-08-06 | 2005-07-05 | New England Medical Hospitals, Inc. | Drug delivery composition |
| US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
| US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
| TW200404581A (en) * | 2002-04-23 | 2004-04-01 | Alza Corp | Transdermal analgesic systems with reduced abuse potential |
| SI1513532T1 (sl) * | 2002-06-10 | 2007-08-31 | Euro Celtique Sa | Sistemi za odstranjevanje priprav za transdermalno oddajanje za preprečevanje zlorabe učinkovin, ki jih vsebujejo |
| ES2290512T3 (es) * | 2002-08-09 | 2008-02-16 | Grunenthal Gmbh | Antagonistas del receptor opioide en sistemas transdermicos que contienen buprenorfina. |
| ATE444296T1 (de) * | 2002-10-25 | 2009-10-15 | Euro Celtique Sa | Analoga und prodrugs von buprenorphin |
| US7524515B2 (en) * | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
| DE602004024963D1 (de) * | 2003-03-13 | 2010-02-25 | Controlled Chemicals Inc | Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer |
| US20040191301A1 (en) * | 2003-03-27 | 2004-09-30 | Van Duren Albert Philip | Transdermal device having a phase change material |
| US20080020028A1 (en) * | 2003-08-20 | 2008-01-24 | Euro-Celtique S.A. | Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent |
| WO2005025549A2 (en) * | 2003-09-10 | 2005-03-24 | Noven Pharmaceuticals, Inc. | Multi-layer transdermal drug delivery device |
| EP2269606A3 (en) * | 2003-10-30 | 2012-04-25 | ALZA Corporation | Transdermal analgesic systems having reduced abuse potential |
| ES2324719T3 (es) * | 2004-02-23 | 2009-08-13 | Euro-Celtique S.A. | Dispositivo de administracion transdermica de opioides con resistencia al abuso. |
| EP1928881A2 (en) * | 2005-08-19 | 2008-06-11 | Pharmacofore, Inc. | Prodrugs of active agents |
| JP5180092B2 (ja) * | 2005-11-22 | 2013-04-10 | オレキシジェン・セラピューティクス・インコーポレーテッド | インスリン感受性を増すための組成物および方法 |
| EP1968539A2 (en) * | 2005-12-13 | 2008-09-17 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
| WO2008036980A1 (en) * | 2006-09-22 | 2008-03-27 | Alltranz Inc. | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof |
-
2009
- 2009-03-26 US US12/412,189 patent/US20090246265A1/en not_active Abandoned
- 2009-03-26 JP JP2011502067A patent/JP2011515495A/ja active Pending
- 2009-03-26 MX MX2010010512A patent/MX2010010512A/es not_active Application Discontinuation
- 2009-03-26 WO PCT/US2009/038439 patent/WO2009120889A2/en not_active Ceased
- 2009-03-26 EP EP09725804A patent/EP2254561A2/en not_active Withdrawn
- 2009-03-26 CA CA2718943A patent/CA2718943A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011515495A5 (enExample) | ||
| JP2010189403A5 (enExample) | ||
| US5149538A (en) | Misuse-resistive transdermal opioid dosage form | |
| CA2795158C (en) | Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists | |
| JP2006524261A5 (enExample) | ||
| EP1530469B1 (en) | Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist | |
| US10238648B2 (en) | Abuse deterrent opioid/opioid-antagonist transdermal patch | |
| CA2519556A1 (en) | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same | |
| JP2009541320A5 (enExample) | ||
| US20080020028A1 (en) | Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent | |
| JP2011126895A5 (enExample) | ||
| CA2654700A1 (en) | Transdermal patch | |
| US20190328681A1 (en) | Transdermal patch | |
| CA2547334A1 (en) | Methods and compositions for deterring abuse of opioid containing dosage forms | |
| RU2011135568A (ru) | Защищенная от применения не по назначению экструдированная из расплава композиция с уменьшенным взаимодействием со спиртом | |
| SI1551372T1 (en) | SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES | |
| JP2009545561A5 (enExample) | ||
| CA2640339A1 (en) | Tamper resistant opioid dosage forms | |
| HRP20150835T1 (hr) | Farmaceutski oblici doziranja s kontroliranim oslobađanjem | |
| JP2012519675A5 (enExample) | ||
| RU2009101082A (ru) | Фармацевтические композиции | |
| JP2011519930A5 (enExample) | ||
| JP2013541567A5 (enExample) | ||
| RU2017112301A (ru) | Стойкие к злоупотреблению фармацевтические композиции | |
| NZ589627A (en) | Pharmaceutical compositions comprising an opioid and a 4-(2-furanyl)thiazole compound for suppressing undesirable effects of opioids |